PT-141 Mechanism & Pharmacology: Melanocortin Receptor Activation
PT-141 is a synthetic cyclic heptapeptide melanocortin receptor agonist, also known by its international non-proprietary name bremelanotide, developed as a centrally acting compound targeting the melanocortin system rather than the peripheral vascular pathways used by earlier pharmacological agents.
Unlike phosphodiesterase-5 inhibitors, PT-141 works upstream in the central nervous system. Bremelanotide binds the melanocortin-4 receptor (MC4R) and, to a lesser extent, the melanocortin-3 receptor (MC3R), both of which are expressed in hypothalamic nuclei closely associated with autonomic and neuroendocrine regulation of sexual arousal. This mechanism means the compound engages motivational and desire pathways directly in the brain, rather than simply facilitating haemodynamic changes in peripheral tissue. The melanocortin system plays a broad regulatory role in energy homeostasis, inflammation, and reproductive behaviour, which is why PT-141's pharmacological profile is considered genuinely distinct within its class.
Structurally, PT-141 is derived from alpha-melanocyte-stimulating hormone (α-MSH) and shares a scaffold with the earlier research compound Melanotan II, though it has been optimised to remove the tanning activity associated with that peptide's MC1R agonism. The compound carries a molecular weight of approximately 1025 Da and is typically reconstituted from a lyophilised powder for subcutaneous administration. Following injection, peak plasma concentrations are reached within approximately 60 to 90 minutes. The elimination half-life is reported at roughly 2.7 hours in human pharmacokinetic studies, providing a relatively contained window of activity that aligns with single-occasion research protocols. Bioavailability via the subcutaneous route is substantially higher than oral administration, which makes the injectable vial format the standard presentation for research use.
At a receptor level, PT-141 activates the Gαs-coupled signalling cascade downstream of MC4R, elevating intracellular cyclic AMP (cAMP) concentrations and modulating neuronal excitability in regions including the paraventricular nucleus of the hypothalamus. This cascade is understood to contribute to pro-erectile signalling in male subjects and increased sexual receptivity in female subjects in preclinical models, observations that eventually led to regulatory approval of the subcutaneous auto-injector formulation (Vyleesi®) in the United States in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Application Context & User Groups
The primary context in which PT-141 has been investigated involves sexual dysfunction research, spanning both male erectile dysfunction and female hypoactive sexual desire disorder. Because its mechanism of action bypasses vascular dependence, PT-141 has attracted research interest specifically among populations where vascular-pathway agents are contraindicated or insufficiently effective — including individuals with diabetes-related vascular compromise or neurogenic erectile dysfunction where peripheral blood flow modulation alone is insufficient.
In male subjects, clinical research documented meaningful improvements in erectile function scores using doses in the 1.25 mg to 10 mg range, with a published Phase II trial in men with erectile dysfunction reporting statistically significant responses at the higher dose tiers. Notably, the responder profile included men who had previously shown inadequate results with sildenafil, positioning PT-141 as a mechanistically complementary rather than redundant option in that body of work.
For researchers and specialist practitioners working within approved study frameworks, PT-141 also presents interest due to its potential for application regardless of sexual stimulation timing — unlike agents that require sexual stimulation coincident with peak plasma concentration. This property relates directly to its central, desire-pathway mechanism and has been cited in research literature as a potentially meaningful practical distinction.
Within the bodybuilding and performance research community, PT-141 occupies a niche that is somewhat separate from the core anabolic peptide stack. Its use is not directed at body composition, muscle protein synthesis, or recovery enhancement. Instead, individuals in high-intensity training phases sometimes report interest in compounds that address libido suppression associated with caloric restriction, high training volume, or endocrine disruption from anabolic protocols — contexts in which central melanocortin signalling may be blunted. This represents an adjacent, though plausible, application context noted in experiential literature, distinct from its clinical trial evidence base.
Those sourcing PT-141 for legitimate research purposes should be aware that the compound requires careful handling as a lyophilised peptide: storage at 2–8°C prior to reconstitution, use of bacteriostatic water for reconstitution, and prompt use or appropriate cold storage of reconstituted solution to maintain peptide integrity.
Range & Selection by Concentration and Pack Size
PT-141 is available in this category at the established research-standard concentration of 10mg per vial, presented in single-vial packs. This concentration tier reflects the upper end of doses investigated in human clinical trials and provides flexibility for both lower-dose and higher-dose research protocols when accurate reconstitution volumes are applied.
The sole representative product in this category is PT-141 10mg/vial 1 Vial by Knoll Pharmaceuticals. Knoll Pharmaceuticals manufactures this product as a lyophilised powder format, consistent with industry-standard peptide preservation practice. The 10mg concentration is particularly appropriate for researchers who wish to prepare multiple measured doses from a single vial — for example, reconstituting in 2 mL bacteriostatic water to yield a 5mg/mL solution, from which individual research doses can be precisely drawn.
For researchers new to melanocortin peptides, the 10mg vial offers sufficient quantity to conduct structured observation across multiple time points without requiring immediate reorder, while remaining a contained enough quantity that storage integrity is straightforward to maintain. For those with prior experience of this compound class, the 10mg concentration matches published clinical dosing ranges directly and requires no upward reconstitution adjustment to reach effective research concentrations.
As this category expands, additional manufacturer options and potentially alternative vial sizes may be listed; at present, the Knoll Pharmaceuticals 10mg offering represents the definitive choice for UK and international researchers seeking a verified, clearly dosed PT-141 product in this category.
Frequently Asked Questions
What is PT-141 and how does it differ from other peptides used in research?
PT-141 (bremelanotide) is a melanocortin-4 receptor agonist that acts centrally in the brain rather than on peripheral vascular tissue. This distinguishes it from compounds like sildenafil or tadalafil, which target phosphodiesterase enzymes. Its action on hypothalamic desire and arousal pathways makes it mechanistically unique among compounds researched for sexual function.
What concentration of PT-141 is available, and is a single vial sufficient for a research protocol?
The available concentration in this category is 10mg per vial from Knoll Pharmaceuticals. When reconstituted in 1–2 mL bacteriostatic water, this yields sufficient volume for several measured research doses, typically providing multiple data points within a single structured protocol without requiring immediate restocking.
How should PT-141 vials be stored to maintain peptide integrity?
Lyophilised PT-141 powder should be stored refrigerated at 2–8°C and kept away from light. Once reconstituted, the solution should be kept refrigerated and used within an appropriate window — generally cited in research practice as up to 28 days — to prevent peptide degradation and maintain research consistency.
Lab Tested